| HOME >> BIOLOGY >> TECHNOLOGY |
Remodulin and Tyvaso are registered trademarks of United Therapeutics Corporation.
Adcirca is a registered trademark of Eli Lilly and Company.
UNITED THERAPEUTICS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)Three Months EndedSeptember 30,Nine Months Ended September 30,2011201020112010(Unaudited)(Unaudited)Revenues:Net product sales
$
201,020$
168,236$
546,784$
428,306License fees
7223391,221903Total revenues
201,742168,575548,005429,209Operating expenses:Research and development
59,43340,337131,379103,391Selling, general and administrative
16,65645,59398,775120,699Cost of product sales
22,67620,15563,57749,139Total operating expenses
98,765106,085293,731273,229Operating income
102,97762,490254,274155,980Other (expense) income:Interest income
1,0165642,5202,308Interest expense
(5,416)(4,809)(16,256)(14,255)Equity loss in affiliate
(43)(39)(110)(130)Other, net
(278)137(1,301)457Total other (expense) income, net
(4,721)(4,147)(15,147)(11,620)Income from continuing operations before income taxes
98,25658,343239,127144,360Income tax expense
(17,641)(18,217)(65,073)(47,332)Income from continuing operations
80,61540,126174,05497,028Discontinued operations:(Loss) income from discontinued operations, net of tax
—(390)7(656)Gain on disposal of discontinued operations, net of tax
3,783—618—Income (loss) from discontinued operations
3,783(390)625(656)Net income
$
84,398$
39,736$
174,679$
96,372Net income per common share:BasicContinuing operations
$
1.38$
0.71$
3.00$
1.74Discontinued operations
$
0.07$
(0.01)$
0.01$
(0.01)Net income per ba
'/>"/>
| SOURCE United Therapeutics Corporation Copyright©2010 PR Newswire. All rights reserved |